A Trial of PDL192 in Subjects With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

NCT07337525

Advanced Malignant Solid Tumor Solid Tumor Cancer

NOT_YET_RECRUITING PHASE1

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

NCT03700294

Advanced Solid Tumors

TERMINATED PHASE1

Intratumoral N17350 in Advanced Solid Tumors

NCT07339176

Neoplasms, Solid Tumor Breast Neoplasms, Triple-Negative Squamous Cell Carcinoma of Skin +4 more

NOT_YET_RECRUITING PHASE1/PHASE2

First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

NCT01323933

Neoplasms

COMPLETED PHASE1

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

NCT03831295

Advanced Malignant Solid Neoplasm Extracranial Solid Neoplasm Metastatic Malignant Solid Neoplasm

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary study objective is to determine the maximum tolerated dose of PDL192 in subjects with advanced solid tumors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type BIOLOGICAL

Humanized anti-TWEAK receptor monoclonal IgG1 antibody

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PDL192

Humanized anti-TWEAK receptor monoclonal IgG1 antibody

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:

1. Male or female, 18 years of age or older.
2. Subjects with documented advanced solid tumors.
3. Subjects who have previously failed all standard therapies or subjects who have a tumor where no standard therapy exists.
4. A negative serum pregnancy test (women of childbearing potential only) at screening. Male or female subjects of reproductive potential must be willing to use adequate contraception during the duration of the study and for a minimum of 3 months after the end of treatment.
5. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).

Exclusion Criteria

Subjects will be ineligible for this study if they meet any one of the following criteria:

1. Symptomatic and progressive central nervous system (CNS) metastases or leptomeningeal metastases
2. Diagnosis of glioblastoma
3. Eastern Cooperative Oncology Group (ECOG) performance status \>= 2
4. Abnormal hematologic values defined as:

* Hemoglobin level \< 9 g/dL
* Absolute neutrophil count (ANC) \< 1500/mm3
* Platelet count \< 100,000/mm3
5. Abnormal kidney, liver, or pancreatic function defined as:

* Serum creatinine \> 1.5 x upper limit of normal value (ULN)
* Aspartate transaminase or alanine transaminase levels of \> = 2.5 x ULN
* Bilirubin \> ULN
* Amylase \> 1.5 x ULN
* Lipase \> 1.5 x ULN
6. Known chronic viral hepatitis
7. History of cirrhotic liver disease
8. History of pancreatitis (patients with history of gall stone pancreatitis who are status post-cholecystectomy will be eligible)
9. Acute cholecystitis within 6 months prior to the first dose of study drug
10. Treatment with any investigational drug, antineoplastic agent, or antibodies within 21 days prior to the first dose of study drug (6 weeks for vaccines or nitrosureas)
11. Proteinuria \>1 g/24 hours (only subjects with \> = 2+ with dipstick test will undergo 24 hour urine collection)
12. Ongoing \>= Grade 2 toxicities resulting from prior therapies
13. Received continuous systemic steroids at doses greater than 10 mg/day of prednisone or its equivalent within 30 days prior to the first dose of study drug (intermittent dexamethasone given for prophylaxis or treatment of emesis is permitted)
14. Received any immunosuppressive agent (except steroids) within 21 days prior to the first dose of study drug
15. Known hypersensitivity to any component of the PDL192 formulation
16. Uncontrolled medical problems such as diabetes mellitus, pancreatitis, coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary disease, or symptomatic heart failure
17. Female subjects who are pregnant or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No